RCT of monoclonal antibodies for the treatment of EG/EGE
| Monoclonal antibody | Target | Author | Design | Study population | Dose | Primary outcome |
|---|---|---|---|---|---|---|
| Benralizumab | IL5Rα | Kuang et al. [31] | Placebo-controlled, phase 2 RCT (primary focused on HES) | n 7 (adults) | 30 mg subcutaneously given every 4 weeks, followed by open-label 30 mg subcutaneously given every 4 weeks for up to 48 weeks. | At week 12 reduction of at least 50% in the absolute eosinophil count |
| Omalizumab | IgE | Foroughi et al. [35] | Open-label clinical trial | n 9 (adolescents and adults) | Dosage depending on body weight and total IgE every 2 weeks for a total of 8 doses | Efficacy of anti-IgE therapy in EGIDs and investigate the role of IgE in disease pathogenesis |
| Lirentelimab (AK002) | Siglec-8 | Dellon et al. [37] | Placebo-controlled, phase 2 RCT | n 65 (adults) | 0.3–1.0 mg/kg, 0.3–3.0 mg/kg (4 i.v. doses every 4 weeks), or placebo | At week 12 change in peak gastric/duodenal eosinophil count |
i.v.: intravenous
